XML 102 R83.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-Based Payments (Details) - USD ($)
$ in Millions
3 Months Ended
Sep. 26, 2023
Mar. 31, 2024
Mar. 31, 2023
Share-based Compensation Expense included in consolidated statements of income      
Share-based compensation expense   $ (76.1) $ (78.9)
Subtotal   71.4 81.4
Capitalized share-based compensation costs   (3.3) (3.3)
Share-based compensation expense included in total costs and expenses   68.1 78.1
Income tax effect   (12.9) (14.7)
Selling, General and Administrative Expense   581.5 605.0
Reata Pharmaceuticals, Inc      
Share-based Compensation Expense included in consolidated statements of income      
Operating expenses $ 393.4    
Selling, General and Administrative Expense 196.4    
Research and development expense asset acquired $ 197.0    
Research and development      
Share-based Compensation Expense included in consolidated statements of income      
Share-based compensation expense   27.4 31.3
Selling, general and administrative      
Share-based Compensation Expense included in consolidated statements of income      
Share-based compensation expense   44.0 50.1
Total share-based compensation expense, net of tax      
Share-based Compensation Expense included in consolidated statements of income      
Share-based compensation expense   $ 55.2 $ 63.4